MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.
Fiche publication
Date publication
novembre 2016
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme
Tous les auteurs :
Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papeix C, Vukusic S, De Sèze J, Debouverie M, Gout O, Clavelou P, Defer G, Laplaud DA, Moreau T, Labauge P, Brochet B, Sedel F, Pelletier J,
Lien Pubmed
Résumé
Treatment with MD1003 (high-dose biotin) showed promising results in progressive multiple sclerosis (MS) in a pilot open-label study.
Mots clés
Adult, Biotin, administration & dosage, Disease Progression, Double-Blind Method, Female, Humans, Male, Middle Aged, Multiple Sclerosis, Chronic Progressive, drug therapy, Outcome Assessment (Health Care), Vitamin B Complex, administration & dosage
Référence
Mult. Scler.. 2016 11;22(13):1719-1731